# Addex Therapeutics (ADXN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ADXN
## Company Profile
- Ticker: ADXN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Switzerland and trades in the U
- Tags: CNS
## Stock Data
- Close: 5.8 USD
- Market cap: 8101401.600000001 USD
- Last updated: 2026-08-06
## Business Overview
### Allosteric Modulator Developer
Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. Its strategy combines internally controlled programs, partnered assets, and economic exposure to a broader pipeline advanced through the Neurosterix spinout.
### Internally Controlled Programs
Lead candidate dipraglurant is an mGlu5 negative allosteric modulator with potential applications in recovery from brain injury, stroke, and traumatic brain injury. Addex also has a GABAB positive allosteric modulator program for chronic cough.
### Partnered Development Model
Indivior is developing an Addex-originated GABAB PAM for substance use disorders. This partnership model allows Addex to retain program economics while external collaborators fund and operate selected development programs.
### Neurosterix Exposure
Addex holds a 20% interest in Neurosterix, which is advancing M4 PAM and mGlu7 NAM programs for schizophrenia, psychosis, mood disorders, and other central nervous system conditions.
## Why The Stock Is Moving

Current closing-price context is not available for ADXN.

## Future Catalysts

- Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.

## Recent News
- 2026-07-08 05:00 EST — [Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness](https://biopharmsignal.com/news/ADXN/addex-announces-publication-of-research-highlighting-therapeutic-potential-of-mg-565b76c5) — Source: Addex Therapeutics
- 2026-06-30 05:00 EST — [Addex Shareholders Approve All Resolutions at Annual General Meeting](https://biopharmsignal.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-94ea959e) — Source: Addex Therapeutics
- 2026-06-25 05:00 EST — [Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ADXN/addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-7b0b3a95) — Source: Addex Therapeutics
- 2026-06-22 05:00 EST — [Addex Therapeutics to Report 2026 First Quarter Financial Results  and Host Conference Call on June 25, 2026](https://biopharmsignal.com/news/ADXN/addex-therapeutics-to-report-2026-first-quarter-financial-results-and-host-confe-561a3fbc) — Source: Addex Therapeutics
- 2026-06-05 05:00 EST — [Addex Convenes Annual General Meeting 2026](https://biopharmsignal.com/news/ADXN/addex-convenes-annual-general-meeting-2026-d5a3fe38) — Source: Addex Therapeutics